nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—ankylosing spondylitis—systemic scleroderma	0.17	0.277	CtDrD
Methotrexate—systemic lupus erythematosus—systemic scleroderma	0.162	0.264	CtDrD
Methotrexate—rheumatoid arthritis—systemic scleroderma	0.153	0.25	CtDrD
Methotrexate—psoriasis—systemic scleroderma	0.128	0.209	CtDrD
Methotrexate—SLCO1B3—Mycophenolate mofetil—systemic scleroderma	0.0372	0.165	CbGbCtD
Methotrexate—ABCG2—Leflunomide—systemic scleroderma	0.0279	0.124	CbGbCtD
Methotrexate—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0217	0.0963	CbGbCtD
Methotrexate—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.019	0.0846	CbGbCtD
Methotrexate—SLCO1A2—Prednisone—systemic scleroderma	0.0184	0.0816	CbGbCtD
Methotrexate—SLC22A6—Captopril—systemic scleroderma	0.0177	0.0786	CbGbCtD
Methotrexate—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0172	0.0765	CbGbCtD
Methotrexate—ALB—Captopril—systemic scleroderma	0.0151	0.067	CbGbCtD
Methotrexate—ALB—Mycophenolate mofetil—systemic scleroderma	0.0119	0.0527	CbGbCtD
Methotrexate—ABCB1—Lisinopril—systemic scleroderma	0.0105	0.0468	CbGbCtD
Methotrexate—ALB—Prednisone—systemic scleroderma	0.00949	0.0421	CbGbCtD
Methotrexate—ABCB1—Captopril—systemic scleroderma	0.00789	0.035	CbGbCtD
Methotrexate—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00621	0.0276	CbGbCtD
Methotrexate—ABCB1—Prednisone—systemic scleroderma	0.00496	0.022	CbGbCtD
Methotrexate—MTHFR—artery—systemic scleroderma	0.00135	0.0447	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—CSF1—systemic scleroderma	0.00133	0.134	CbGpPWpGaD
Methotrexate—MTHFR—blood vessel—systemic scleroderma	0.00105	0.0348	CbGeAlD
Methotrexate—SLC19A1—digestive system—systemic scleroderma	0.000815	0.0269	CbGeAlD
Methotrexate—GGH—smooth muscle tissue—systemic scleroderma	0.000782	0.0259	CbGeAlD
Methotrexate—FOLR1—lung—systemic scleroderma	0.000776	0.0257	CbGeAlD
Methotrexate—GGH—skin of body—systemic scleroderma	0.000772	0.0255	CbGeAlD
Methotrexate—FPGS—connective tissue—systemic scleroderma	0.000752	0.0249	CbGeAlD
Methotrexate—ATIC—connective tissue—systemic scleroderma	0.000727	0.024	CbGeAlD
Methotrexate—SLC19A1—lung—systemic scleroderma	0.000681	0.0225	CbGeAlD
Methotrexate—FPGS—skin of body—systemic scleroderma	0.000679	0.0224	CbGeAlD
Methotrexate—ATIC—smooth muscle tissue—systemic scleroderma	0.000665	0.022	CbGeAlD
Methotrexate—ATIC—skin of body—systemic scleroderma	0.000657	0.0217	CbGeAlD
Methotrexate—SLC46A1—digestive system—systemic scleroderma	0.000628	0.0208	CbGeAlD
Methotrexate—GGH—digestive system—systemic scleroderma	0.000618	0.0204	CbGeAlD
Methotrexate—SLC46A1—tendon—systemic scleroderma	0.000597	0.0198	CbGeAlD
Methotrexate—GGH—tendon—systemic scleroderma	0.000588	0.0194	CbGeAlD
Methotrexate—FPGS—digestive system—systemic scleroderma	0.000543	0.018	CbGeAlD
Methotrexate—SLC19A1—Folate Metabolism—CSF1—systemic scleroderma	0.000531	0.0532	CbGpPWpGaD
Methotrexate—ATIC—digestive system—systemic scleroderma	0.000525	0.0174	CbGeAlD
Methotrexate—FPGS—tendon—systemic scleroderma	0.000517	0.0171	CbGeAlD
Methotrexate—GGH—lung—systemic scleroderma	0.000516	0.0171	CbGeAlD
Methotrexate—TYMS—connective tissue—systemic scleroderma	0.000493	0.0163	CbGeAlD
Methotrexate—DHFR—connective tissue—systemic scleroderma	0.000488	0.0161	CbGeAlD
Methotrexate—PGD—connective tissue—systemic scleroderma	0.000469	0.0155	CbGeAlD
Methotrexate—SLCO4C1—lung—systemic scleroderma	0.000457	0.0151	CbGeAlD
Methotrexate—FPGS—lung—systemic scleroderma	0.000453	0.015	CbGeAlD
Methotrexate—TYMS—smooth muscle tissue—systemic scleroderma	0.000451	0.0149	CbGeAlD
Methotrexate—FOLR1—Folate Metabolism—CCL2—systemic scleroderma	0.00045	0.0451	CbGpPWpGaD
Methotrexate—TYMS—skin of body—systemic scleroderma	0.000445	0.0147	CbGeAlD
Methotrexate—SLCO1B3—lung—systemic scleroderma	0.000445	0.0147	CbGeAlD
Methotrexate—ATIC—lung—systemic scleroderma	0.000439	0.0145	CbGeAlD
Methotrexate—PGD—smooth muscle tissue—systemic scleroderma	0.000429	0.0142	CbGeAlD
Methotrexate—SLC22A11—digestive system—systemic scleroderma	0.000424	0.014	CbGeAlD
Methotrexate—PGD—skin of body—systemic scleroderma	0.000424	0.014	CbGeAlD
Methotrexate—SLC22A7—digestive system—systemic scleroderma	0.000414	0.0137	CbGeAlD
Methotrexate—MTHFR—digestive system—systemic scleroderma	0.00039	0.0129	CbGeAlD
Methotrexate—SLCO3A1—tendon—systemic scleroderma	0.000365	0.0121	CbGeAlD
Methotrexate—TYMS—digestive system—systemic scleroderma	0.000356	0.0118	CbGeAlD
Methotrexate—DHFR—digestive system—systemic scleroderma	0.000353	0.0117	CbGeAlD
Methotrexate—SLC46A1—Folate Metabolism—CSF1—systemic scleroderma	0.000352	0.0353	CbGpPWpGaD
Methotrexate—FOLR1—Folate Metabolism—IL1B—systemic scleroderma	0.000342	0.0342	CbGpPWpGaD
Methotrexate—PGD—digestive system—systemic scleroderma	0.000339	0.0112	CbGeAlD
Methotrexate—TYMS—tendon—systemic scleroderma	0.000339	0.0112	CbGeAlD
Methotrexate—AOX1—Effects of Nitric Oxide—NOS3—systemic scleroderma	0.000338	0.0338	CbGpPWpGaD
Methotrexate—DHFR—tendon—systemic scleroderma	0.000336	0.0111	CbGeAlD
Methotrexate—MTHFR—lung—systemic scleroderma	0.000326	0.0108	CbGeAlD
Methotrexate—PGD—tendon—systemic scleroderma	0.000323	0.0107	CbGeAlD
Methotrexate—SLCO3A1—lung—systemic scleroderma	0.000321	0.0106	CbGeAlD
Methotrexate—SLC16A1—digestive system—systemic scleroderma	0.000316	0.0105	CbGeAlD
Methotrexate—SLCO1B1—digestive system—systemic scleroderma	0.000308	0.0102	CbGeAlD
Methotrexate—SLC16A1—tendon—systemic scleroderma	0.000301	0.00996	CbGeAlD
Methotrexate—AOX1—digestive system—systemic scleroderma	0.000299	0.00987	CbGeAlD
Methotrexate—TYMS—lung—systemic scleroderma	0.000297	0.00983	CbGeAlD
Methotrexate—DHFR—lung—systemic scleroderma	0.000294	0.00974	CbGeAlD
Methotrexate—ABCC3—digestive system—systemic scleroderma	0.000292	0.00966	CbGeAlD
Methotrexate—ABCC10—digestive system—systemic scleroderma	0.000291	0.00961	CbGeAlD
Methotrexate—AOX1—tendon—systemic scleroderma	0.000284	0.0094	CbGeAlD
Methotrexate—PGD—lung—systemic scleroderma	0.000283	0.00936	CbGeAlD
Methotrexate—ABCC10—tendon—systemic scleroderma	0.000277	0.00915	CbGeAlD
Methotrexate—SLC16A1—lung—systemic scleroderma	0.000264	0.00874	CbGeAlD
Methotrexate—SLCO1A2—digestive system—systemic scleroderma	0.000251	0.00828	CbGeAlD
Methotrexate—AOX1—lung—systemic scleroderma	0.000249	0.00825	CbGeAlD
Methotrexate—ABCC3—lung—systemic scleroderma	0.000244	0.00807	CbGeAlD
Methotrexate—ABCC10—lung—systemic scleroderma	0.000243	0.00803	CbGeAlD
Methotrexate—ABCC4—digestive system—systemic scleroderma	0.000241	0.00797	CbGeAlD
Methotrexate—ABCC2—digestive system—systemic scleroderma	0.000233	0.00772	CbGeAlD
Methotrexate—ABCC4—tendon—systemic scleroderma	0.000229	0.00759	CbGeAlD
Methotrexate—ABCB1—blood vessel—systemic scleroderma	0.000227	0.00749	CbGeAlD
Methotrexate—ABCC2—tendon—systemic scleroderma	0.000222	0.00734	CbGeAlD
Methotrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—NOS3—systemic scleroderma	0.000222	0.0223	CbGpPWpGaD
Methotrexate—MTHFR—Folate Metabolism—CSF1—systemic scleroderma	0.000212	0.0213	CbGpPWpGaD
Methotrexate—SLCO1A2—lung—systemic scleroderma	0.000209	0.00692	CbGeAlD
Methotrexate—ABCC4—lung—systemic scleroderma	0.000201	0.00666	CbGeAlD
Methotrexate—ABCC1—tendon—systemic scleroderma	0.000196	0.00647	CbGeAlD
Methotrexate—DHFR—Folate Metabolism—CSF1—systemic scleroderma	0.000189	0.0189	CbGpPWpGaD
Methotrexate—SLC19A1—Folate Metabolism—CCL2—systemic scleroderma	0.000179	0.018	CbGpPWpGaD
Methotrexate—ABCC1—lung—systemic scleroderma	0.000172	0.00568	CbGeAlD
Methotrexate—SLC16A1—Basigin interactions—MMP1—systemic scleroderma	0.000155	0.0155	CbGpPWpGaD
Methotrexate—DHFR—Metabolism of nitric oxide—NOS3—systemic scleroderma	0.000154	0.0154	CbGpPWpGaD
Methotrexate—TYMS—Clobetasol propionate—Mometasone—systemic scleroderma	0.000153	0.117	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Mometasone—systemic scleroderma	0.000151	0.115	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Mometasone—systemic scleroderma	0.00015	0.114	CbGdCrCtD
Methotrexate—TYMS—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000146	0.111	CbGdCrCtD
Methotrexate—ABCG2—lung—systemic scleroderma	0.000142	0.0047	CbGeAlD
Methotrexate—TYMS—Diflorasone—Mometasone—systemic scleroderma	0.000138	0.105	CbGdCrCtD
Methotrexate—SLC19A1—Folate Metabolism—IL1B—systemic scleroderma	0.000136	0.0136	CbGpPWpGaD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—SELP—systemic scleroderma	0.000129	0.0129	CbGpPWpGaD
Methotrexate—TYMS—Budesonide—Mometasone—systemic scleroderma	0.000121	0.0923	CbGdCrCtD
Methotrexate—SLC46A1—Folate Metabolism—CCL2—systemic scleroderma	0.000119	0.0119	CbGpPWpGaD
Methotrexate—ABCC4—Platelet degranulation—SELP—systemic scleroderma	0.000114	0.0114	CbGpPWpGaD
Methotrexate—ABCC4—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000108	0.0109	CbGpPWpGaD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—ITGAM—systemic scleroderma	0.000103	0.0103	CbGpPWpGaD
Methotrexate—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	9.94e-05	0.00996	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	9.87e-05	0.00989	CbGpPWpGaD
Methotrexate—PGD—Carbohydrate metabolism—HSPG2—systemic scleroderma	9.83e-05	0.00986	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TOP1—systemic scleroderma	9.48e-05	0.0095	CbGpPWpGaD
Methotrexate—SLC46A1—Folate Metabolism—IL1B—systemic scleroderma	9.01e-05	0.00903	CbGpPWpGaD
Methotrexate—MTHFR—Vitamin B12 Metabolism—CCL2—systemic scleroderma	8.81e-05	0.00883	CbGpPWpGaD
Methotrexate—ABCB1—digestive system—systemic scleroderma	8.39e-05	0.00278	CbGeAlD
Methotrexate—TYMS—Clobetasol propionate—Prednisone—systemic scleroderma	8.34e-05	0.0637	CbGdCrCtD
Methotrexate—TYMS—Flunisolide—Prednisone—systemic scleroderma	8.24e-05	0.0629	CbGdCrCtD
Methotrexate—TYMS—Triamcinolone—Prednisone—systemic scleroderma	8.15e-05	0.0622	CbGdCrCtD
Methotrexate—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	7.74e-05	0.00776	CbGpPWpGaD
Methotrexate—TYMS—Diflorasone—Prednisone—systemic scleroderma	7.51e-05	0.0574	CbGdCrCtD
Methotrexate—MTHFR—Folate Metabolism—CCL2—systemic scleroderma	7.17e-05	0.00718	CbGpPWpGaD
Methotrexate—ABCB1—lung—systemic scleroderma	7.01e-05	0.00232	CbGeAlD
Methotrexate—DHFR—Cell Cycle, Mitotic—CENPC—systemic scleroderma	6.72e-05	0.00673	CbGpPWpGaD
Methotrexate—MTHFR—Vitamin B12 Metabolism—IL1B—systemic scleroderma	6.68e-05	0.0067	CbGpPWpGaD
Methotrexate—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	6.6e-05	0.00662	CbGpPWpGaD
Methotrexate—TYMS—Budesonide—Prednisone—systemic scleroderma	6.59e-05	0.0503	CbGdCrCtD
Methotrexate—DHFR—Folate Metabolism—CCL2—systemic scleroderma	6.37e-05	0.00638	CbGpPWpGaD
Methotrexate—TYMS—Danazol—Prednisone—systemic scleroderma	6.31e-05	0.0482	CbGdCrCtD
Methotrexate—SLC19A1—Disease—SMAD7—systemic scleroderma	6.3e-05	0.00632	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CENPC—systemic scleroderma	6.01e-05	0.00602	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CENPC—systemic scleroderma	5.86e-05	0.00587	CbGpPWpGaD
Methotrexate—Asthenia—Mometasone—systemic scleroderma	5.84e-05	0.000483	CcSEcCtD
Methotrexate—Irritability—Prednisone—systemic scleroderma	5.84e-05	0.000483	CcSEcCtD
Methotrexate—Eye disorder—Mycophenolate mofetil—systemic scleroderma	5.84e-05	0.000483	CcSEcCtD
Methotrexate—Hypotension—Azathioprine—systemic scleroderma	5.83e-05	0.000482	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	5.83e-05	0.000482	CcSEcCtD
Methotrexate—Tinnitus—Mycophenolate mofetil—systemic scleroderma	5.82e-05	0.000482	CcSEcCtD
Methotrexate—Mood swings—Prednisone—systemic scleroderma	5.8e-05	0.00048	CcSEcCtD
Methotrexate—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	5.8e-05	0.00048	CcSEcCtD
Methotrexate—Discomfort—Mycophenolic acid—systemic scleroderma	5.8e-05	0.000479	CcSEcCtD
Methotrexate—ALB—Folate Metabolism—CSF1—systemic scleroderma	5.79e-05	0.00581	CbGpPWpGaD
Methotrexate—Nervous system disorder—Leflunomide—systemic scleroderma	5.78e-05	0.000478	CcSEcCtD
Methotrexate—Thrombocytopenia—Leflunomide—systemic scleroderma	5.77e-05	0.000477	CcSEcCtD
Methotrexate—SLC19A1—Disease—TGFBI—systemic scleroderma	5.76e-05	0.00578	CbGpPWpGaD
Methotrexate—Pruritus—Mometasone—systemic scleroderma	5.76e-05	0.000477	CcSEcCtD
Methotrexate—Ill-defined disorder—Lisinopril—systemic scleroderma	5.76e-05	0.000476	CcSEcCtD
Methotrexate—Anaemia—Lisinopril—systemic scleroderma	5.74e-05	0.000475	CcSEcCtD
Methotrexate—Skin disorder—Leflunomide—systemic scleroderma	5.73e-05	0.000474	CcSEcCtD
Methotrexate—Hyperhidrosis—Leflunomide—systemic scleroderma	5.7e-05	0.000471	CcSEcCtD
Methotrexate—MTHFR—Selenium Micronutrient Network—CCL2—systemic scleroderma	5.69e-05	0.00571	CbGpPWpGaD
Methotrexate—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	5.69e-05	0.00047	CcSEcCtD
Methotrexate—Confusional state—Mycophenolic acid—systemic scleroderma	5.67e-05	0.000469	CcSEcCtD
Methotrexate—Angiopathy—Mycophenolate mofetil—systemic scleroderma	5.67e-05	0.000469	CcSEcCtD
Methotrexate—Body temperature increased—Captopril—systemic scleroderma	5.65e-05	0.000468	CcSEcCtD
Methotrexate—Abdominal pain—Captopril—systemic scleroderma	5.65e-05	0.000468	CcSEcCtD
Methotrexate—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	5.63e-05	0.000466	CcSEcCtD
Methotrexate—Anorexia—Leflunomide—systemic scleroderma	5.62e-05	0.000465	CcSEcCtD
Methotrexate—Nausea—Pentoxifylline—systemic scleroderma	5.61e-05	0.000464	CcSEcCtD
Methotrexate—Chills—Mycophenolate mofetil—systemic scleroderma	5.6e-05	0.000464	CcSEcCtD
Methotrexate—Malaise—Lisinopril—systemic scleroderma	5.6e-05	0.000463	CcSEcCtD
Methotrexate—Infection—Mycophenolic acid—systemic scleroderma	5.59e-05	0.000462	CcSEcCtD
Methotrexate—Vertigo—Lisinopril—systemic scleroderma	5.58e-05	0.000461	CcSEcCtD
Methotrexate—Diarrhoea—Mometasone—systemic scleroderma	5.57e-05	0.000461	CcSEcCtD
Methotrexate—Leukopenia—Lisinopril—systemic scleroderma	5.55e-05	0.00046	CcSEcCtD
Methotrexate—Alopecia—Mycophenolate mofetil—systemic scleroderma	5.52e-05	0.000457	CcSEcCtD
Methotrexate—Nervous system disorder—Mycophenolic acid—systemic scleroderma	5.51e-05	0.000456	CcSEcCtD
Methotrexate—Hypotension—Leflunomide—systemic scleroderma	5.51e-05	0.000456	CcSEcCtD
Methotrexate—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	5.51e-05	0.000455	CcSEcCtD
Methotrexate—Mental disorder—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000453	CcSEcCtD
Methotrexate—Skin disorder—Mycophenolic acid—systemic scleroderma	5.46e-05	0.000452	CcSEcCtD
Methotrexate—Malnutrition—Mycophenolate mofetil—systemic scleroderma	5.44e-05	0.00045	CcSEcCtD
Methotrexate—MTHFR—Folate Metabolism—IL1B—systemic scleroderma	5.44e-05	0.00545	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	5.44e-05	0.00045	CcSEcCtD
Methotrexate—Cough—Lisinopril—systemic scleroderma	5.42e-05	0.000448	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Azathioprine—systemic scleroderma	5.39e-05	0.000446	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	5.37e-05	0.000444	CcSEcCtD
Methotrexate—Anorexia—Mycophenolic acid—systemic scleroderma	5.36e-05	0.000443	CcSEcCtD
Methotrexate—FPGS—Disease—SMAD7—systemic scleroderma	5.36e-05	0.00537	CbGpPWpGaD
Methotrexate—Insomnia—Leflunomide—systemic scleroderma	5.33e-05	0.000441	CcSEcCtD
Methotrexate—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	5.32e-05	0.00044	CcSEcCtD
Methotrexate—Paraesthesia—Leflunomide—systemic scleroderma	5.29e-05	0.000438	CcSEcCtD
Methotrexate—Arthralgia—Lisinopril—systemic scleroderma	5.28e-05	0.000437	CcSEcCtD
Methotrexate—Chest pain—Lisinopril—systemic scleroderma	5.28e-05	0.000437	CcSEcCtD
Methotrexate—Myalgia—Lisinopril—systemic scleroderma	5.28e-05	0.000437	CcSEcCtD
Methotrexate—Back pain—Mycophenolate mofetil—systemic scleroderma	5.26e-05	0.000435	CcSEcCtD
Methotrexate—Dyspnoea—Leflunomide—systemic scleroderma	5.25e-05	0.000435	CcSEcCtD
Methotrexate—Hypotension—Mycophenolic acid—systemic scleroderma	5.25e-05	0.000435	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	5.25e-05	0.000434	CcSEcCtD
Methotrexate—TYMS—Cell Cycle—CENPC—systemic scleroderma	5.24e-05	0.00525	CbGpPWpGaD
Methotrexate—Discomfort—Lisinopril—systemic scleroderma	5.22e-05	0.000432	CcSEcCtD
Methotrexate—Dyspepsia—Leflunomide—systemic scleroderma	5.19e-05	0.000429	CcSEcCtD
Methotrexate—Pancreatitis—Prednisone—systemic scleroderma	5.19e-05	0.000429	CcSEcCtD
Methotrexate—Vomiting—Mometasone—systemic scleroderma	5.18e-05	0.000428	CcSEcCtD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—MMP1—systemic scleroderma	5.16e-05	0.00517	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—SELP—systemic scleroderma	5.15e-05	0.00516	CbGpPWpGaD
Methotrexate—Feeling abnormal—Azathioprine—systemic scleroderma	5.14e-05	0.000426	CcSEcCtD
Methotrexate—Rash—Mometasone—systemic scleroderma	5.13e-05	0.000425	CcSEcCtD
Methotrexate—Asthenia—Captopril—systemic scleroderma	5.13e-05	0.000424	CcSEcCtD
Methotrexate—Dermatitis—Mometasone—systemic scleroderma	5.13e-05	0.000424	CcSEcCtD
Methotrexate—Decreased appetite—Leflunomide—systemic scleroderma	5.12e-05	0.000424	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	5.12e-05	0.000424	CcSEcCtD
Methotrexate—Confusional state—Lisinopril—systemic scleroderma	5.11e-05	0.000422	CcSEcCtD
Methotrexate—Gastrointestinal pain—Azathioprine—systemic scleroderma	5.1e-05	0.000422	CcSEcCtD
Methotrexate—Headache—Mometasone—systemic scleroderma	5.1e-05	0.000422	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Leflunomide—systemic scleroderma	5.09e-05	0.000421	CcSEcCtD
Methotrexate—Insomnia—Mycophenolic acid—systemic scleroderma	5.09e-05	0.000421	CcSEcCtD
Methotrexate—Fatigue—Leflunomide—systemic scleroderma	5.08e-05	0.00042	CcSEcCtD
Methotrexate—Anaphylactic shock—Lisinopril—systemic scleroderma	5.06e-05	0.000419	CcSEcCtD
Methotrexate—Pruritus—Captopril—systemic scleroderma	5.06e-05	0.000419	CcSEcCtD
Methotrexate—Paraesthesia—Mycophenolic acid—systemic scleroderma	5.05e-05	0.000418	CcSEcCtD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	5.05e-05	0.00506	CbGpPWpGaD
Methotrexate—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	5.04e-05	0.000417	CcSEcCtD
Methotrexate—Pain—Leflunomide—systemic scleroderma	5.04e-05	0.000417	CcSEcCtD
Methotrexate—Infection—Lisinopril—systemic scleroderma	5.03e-05	0.000416	CcSEcCtD
Methotrexate—Anaemia—Mycophenolate mofetil—systemic scleroderma	5.03e-05	0.000416	CcSEcCtD
Methotrexate—Dyspnoea—Mycophenolic acid—systemic scleroderma	5.01e-05	0.000415	CcSEcCtD
Methotrexate—Somnolence—Mycophenolic acid—systemic scleroderma	5e-05	0.000414	CcSEcCtD
Methotrexate—Thrombocytopenia—Lisinopril—systemic scleroderma	4.96e-05	0.00041	CcSEcCtD
Methotrexate—Dyspepsia—Mycophenolic acid—systemic scleroderma	4.95e-05	0.000409	CcSEcCtD
Methotrexate—Neutropenia—Prednisone—systemic scleroderma	4.95e-05	0.000409	CcSEcCtD
Methotrexate—Body temperature increased—Azathioprine—systemic scleroderma	4.93e-05	0.000408	CcSEcCtD
Methotrexate—Abdominal pain—Azathioprine—systemic scleroderma	4.93e-05	0.000408	CcSEcCtD
Methotrexate—Skin disorder—Lisinopril—systemic scleroderma	4.92e-05	0.000407	CcSEcCtD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	4.91e-05	0.00492	CbGpPWpGaD
Methotrexate—Malaise—Mycophenolate mofetil—systemic scleroderma	4.9e-05	0.000406	CcSEcCtD
Methotrexate—FPGS—Disease—TGFBI—systemic scleroderma	4.9e-05	0.00491	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Lisinopril—systemic scleroderma	4.9e-05	0.000405	CcSEcCtD
Methotrexate—Diarrhoea—Captopril—systemic scleroderma	4.89e-05	0.000405	CcSEcCtD
Methotrexate—Decreased appetite—Mycophenolic acid—systemic scleroderma	4.89e-05	0.000404	CcSEcCtD
Methotrexate—Vertigo—Mycophenolate mofetil—systemic scleroderma	4.89e-05	0.000404	CcSEcCtD
Methotrexate—Erectile dysfunction—Prednisone—systemic scleroderma	4.87e-05	0.000403	CcSEcCtD
Methotrexate—Leukopenia—Mycophenolate mofetil—systemic scleroderma	4.87e-05	0.000403	CcSEcCtD
Methotrexate—Feeling abnormal—Leflunomide—systemic scleroderma	4.86e-05	0.000402	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	4.85e-05	0.000402	CcSEcCtD
Methotrexate—Fatigue—Mycophenolic acid—systemic scleroderma	4.85e-05	0.000401	CcSEcCtD
Methotrexate—Nausea—Mometasone—systemic scleroderma	4.84e-05	0.0004	CcSEcCtD
Methotrexate—DHFR—Folate Metabolism—IL1B—systemic scleroderma	4.83e-05	0.00484	CbGpPWpGaD
Methotrexate—Anorexia—Lisinopril—systemic scleroderma	4.83e-05	0.000399	CcSEcCtD
Methotrexate—Gastrointestinal pain—Leflunomide—systemic scleroderma	4.82e-05	0.000399	CcSEcCtD
Methotrexate—Pain—Mycophenolic acid—systemic scleroderma	4.81e-05	0.000398	CcSEcCtD
Methotrexate—Cough—Mycophenolate mofetil—systemic scleroderma	4.74e-05	0.000393	CcSEcCtD
Methotrexate—Hypotension—Lisinopril—systemic scleroderma	4.73e-05	0.000392	CcSEcCtD
Methotrexate—Dizziness—Captopril—systemic scleroderma	4.73e-05	0.000391	CcSEcCtD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	4.71e-05	0.00472	CbGpPWpGaD
Methotrexate—Convulsion—Mycophenolate mofetil—systemic scleroderma	4.71e-05	0.00039	CcSEcCtD
Methotrexate—Depression—Prednisone—systemic scleroderma	4.7e-05	0.000389	CcSEcCtD
Methotrexate—Urticaria—Leflunomide—systemic scleroderma	4.68e-05	0.000387	CcSEcCtD
Methotrexate—Body temperature increased—Leflunomide—systemic scleroderma	4.66e-05	0.000385	CcSEcCtD
Methotrexate—Abdominal pain—Leflunomide—systemic scleroderma	4.66e-05	0.000385	CcSEcCtD
Methotrexate—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	4.64e-05	0.00465	CbGpPWpGaD
Methotrexate—Feeling abnormal—Mycophenolic acid—systemic scleroderma	4.63e-05	0.000383	CcSEcCtD
Methotrexate—Chest pain—Mycophenolate mofetil—systemic scleroderma	4.63e-05	0.000383	CcSEcCtD
Methotrexate—Arthralgia—Mycophenolate mofetil—systemic scleroderma	4.63e-05	0.000383	CcSEcCtD
Methotrexate—Myalgia—Mycophenolate mofetil—systemic scleroderma	4.63e-05	0.000383	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	4.61e-05	0.000382	CcSEcCtD
Methotrexate—Hypersensitivity—Azathioprine—systemic scleroderma	4.6e-05	0.00038	CcSEcCtD
Methotrexate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	4.6e-05	0.00038	CcSEcCtD
Methotrexate—SLC19A1—Disease—HSPG2—systemic scleroderma	4.6e-05	0.00461	CbGpPWpGaD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	4.6e-05	0.00038	CcSEcCtD
Methotrexate—Insomnia—Lisinopril—systemic scleroderma	4.58e-05	0.000379	CcSEcCtD
Methotrexate—Discomfort—Mycophenolate mofetil—systemic scleroderma	4.57e-05	0.000378	CcSEcCtD
Methotrexate—Paraesthesia—Lisinopril—systemic scleroderma	4.55e-05	0.000376	CcSEcCtD
Methotrexate—Vomiting—Captopril—systemic scleroderma	4.55e-05	0.000376	CcSEcCtD
Methotrexate—Dyspnoea—Lisinopril—systemic scleroderma	4.52e-05	0.000374	CcSEcCtD
Methotrexate—Rash—Captopril—systemic scleroderma	4.51e-05	0.000373	CcSEcCtD
Methotrexate—Dermatitis—Captopril—systemic scleroderma	4.51e-05	0.000373	CcSEcCtD
Methotrexate—Somnolence—Lisinopril—systemic scleroderma	4.5e-05	0.000372	CcSEcCtD
Methotrexate—Headache—Captopril—systemic scleroderma	4.48e-05	0.000371	CcSEcCtD
Methotrexate—Confusional state—Mycophenolate mofetil—systemic scleroderma	4.47e-05	0.00037	CcSEcCtD
Methotrexate—Dyspepsia—Lisinopril—systemic scleroderma	4.46e-05	0.000369	CcSEcCtD
Methotrexate—Abdominal pain—Mycophenolic acid—systemic scleroderma	4.45e-05	0.000368	CcSEcCtD
Methotrexate—Body temperature increased—Mycophenolic acid—systemic scleroderma	4.45e-05	0.000368	CcSEcCtD
Methotrexate—SLC19A1—Disease—CSK—systemic scleroderma	4.44e-05	0.00445	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	4.44e-05	0.000367	CcSEcCtD
Methotrexate—Infection—Mycophenolate mofetil—systemic scleroderma	4.41e-05	0.000365	CcSEcCtD
Methotrexate—Decreased appetite—Lisinopril—systemic scleroderma	4.4e-05	0.000364	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	4.37e-05	0.000362	CcSEcCtD
Methotrexate—Fatigue—Lisinopril—systemic scleroderma	4.37e-05	0.000361	CcSEcCtD
Methotrexate—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	4.35e-05	0.00036	CcSEcCtD
Methotrexate—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	4.34e-05	0.000359	CcSEcCtD
Methotrexate—Hypersensitivity—Leflunomide—systemic scleroderma	4.34e-05	0.000359	CcSEcCtD
Methotrexate—Pain—Lisinopril—systemic scleroderma	4.33e-05	0.000358	CcSEcCtD
Methotrexate—MTHFR—Selenium Micronutrient Network—IL1B—systemic scleroderma	4.32e-05	0.00433	CbGpPWpGaD
Methotrexate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000357	CcSEcCtD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	4.29e-05	0.0043	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.29e-05	0.000355	CcSEcCtD
Methotrexate—Diarrhoea—Azathioprine—systemic scleroderma	4.27e-05	0.000353	CcSEcCtD
Methotrexate—DHFR—Cell Cycle, Mitotic—CENPA—systemic scleroderma	4.27e-05	0.00428	CbGpPWpGaD
Methotrexate—Haemoglobin—Prednisone—systemic scleroderma	4.26e-05	0.000352	CcSEcCtD
Methotrexate—Nausea—Captopril—systemic scleroderma	4.25e-05	0.000351	CcSEcCtD
Methotrexate—Haemorrhage—Prednisone—systemic scleroderma	4.23e-05	0.00035	CcSEcCtD
Methotrexate—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.23e-05	0.00035	CcSEcCtD
Methotrexate—Asthenia—Leflunomide—systemic scleroderma	4.23e-05	0.00035	CcSEcCtD
Methotrexate—SLC46A1—Disease—SMAD7—systemic scleroderma	4.18e-05	0.00418	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CD247—systemic scleroderma	4.18e-05	0.00418	CbGpPWpGaD
Methotrexate—Feeling abnormal—Lisinopril—systemic scleroderma	4.17e-05	0.000345	CcSEcCtD
Methotrexate—Pruritus—Leflunomide—systemic scleroderma	4.17e-05	0.000345	CcSEcCtD
Methotrexate—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.15e-05	0.000343	CcSEcCtD
Methotrexate—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.14e-05	0.000343	CcSEcCtD
Methotrexate—Dizziness—Azathioprine—systemic scleroderma	4.13e-05	0.000341	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.04e-05	0.000334	CcSEcCtD
Methotrexate—Asthenia—Mycophenolic acid—systemic scleroderma	4.03e-05	0.000334	CcSEcCtD
Methotrexate—Diarrhoea—Leflunomide—systemic scleroderma	4.03e-05	0.000334	CcSEcCtD
Methotrexate—Urticaria—Lisinopril—systemic scleroderma	4.02e-05	0.000333	CcSEcCtD
Methotrexate—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.01e-05	0.000332	CcSEcCtD
Methotrexate—Abdominal pain—Lisinopril—systemic scleroderma	4e-05	0.000331	CcSEcCtD
Methotrexate—Body temperature increased—Lisinopril—systemic scleroderma	4e-05	0.000331	CcSEcCtD
Methotrexate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	3.98e-05	0.00033	CcSEcCtD
Methotrexate—Pruritus—Mycophenolic acid—systemic scleroderma	3.98e-05	0.000329	CcSEcCtD
Methotrexate—Vomiting—Azathioprine—systemic scleroderma	3.97e-05	0.000328	CcSEcCtD
Methotrexate—Eye disorder—Prednisone—systemic scleroderma	3.96e-05	0.000327	CcSEcCtD
Methotrexate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	3.96e-05	0.000327	CcSEcCtD
Methotrexate—Somnolence—Mycophenolate mofetil—systemic scleroderma	3.95e-05	0.000326	CcSEcCtD
Methotrexate—Rash—Azathioprine—systemic scleroderma	3.94e-05	0.000326	CcSEcCtD
Methotrexate—Dermatitis—Azathioprine—systemic scleroderma	3.93e-05	0.000325	CcSEcCtD
Methotrexate—Headache—Azathioprine—systemic scleroderma	3.91e-05	0.000323	CcSEcCtD
Methotrexate—FPGS—Disease—HSPG2—systemic scleroderma	3.91e-05	0.00392	CbGpPWpGaD
Methotrexate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	3.91e-05	0.000323	CcSEcCtD
Methotrexate—Dizziness—Leflunomide—systemic scleroderma	3.9e-05	0.000322	CcSEcCtD
Methotrexate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	3.86e-05	0.000319	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—HSPG2—systemic scleroderma	3.85e-05	0.00386	CbGpPWpGaD
Methotrexate—Diarrhoea—Mycophenolic acid—systemic scleroderma	3.85e-05	0.000318	CcSEcCtD
Methotrexate—Angiopathy—Prednisone—systemic scleroderma	3.84e-05	0.000318	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000317	CcSEcCtD
Methotrexate—Immune system disorder—Prednisone—systemic scleroderma	3.82e-05	0.000316	CcSEcCtD
Methotrexate—PGD—Disease—SMAD7—systemic scleroderma	3.82e-05	0.00383	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TGFBI—systemic scleroderma	3.82e-05	0.00383	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CENPA—systemic scleroderma	3.81e-05	0.00382	CbGpPWpGaD
Methotrexate—Pain—Mycophenolate mofetil—systemic scleroderma	3.79e-05	0.000314	CcSEcCtD
Methotrexate—FPGS—Disease—CSK—systemic scleroderma	3.78e-05	0.00378	CbGpPWpGaD
Methotrexate—Vomiting—Leflunomide—systemic scleroderma	3.75e-05	0.00031	CcSEcCtD
Methotrexate—Alopecia—Prednisone—systemic scleroderma	3.74e-05	0.00031	CcSEcCtD
Methotrexate—Hypersensitivity—Lisinopril—systemic scleroderma	3.73e-05	0.000309	CcSEcCtD
Methotrexate—TYMS—Cell Cycle, Mitotic—CENPA—systemic scleroderma	3.72e-05	0.00373	CbGpPWpGaD
Methotrexate—Dizziness—Mycophenolic acid—systemic scleroderma	3.72e-05	0.000308	CcSEcCtD
Methotrexate—Rash—Leflunomide—systemic scleroderma	3.72e-05	0.000307	CcSEcCtD
Methotrexate—Dermatitis—Leflunomide—systemic scleroderma	3.71e-05	0.000307	CcSEcCtD
Methotrexate—Mental disorder—Prednisone—systemic scleroderma	3.71e-05	0.000307	CcSEcCtD
Methotrexate—Nausea—Azathioprine—systemic scleroderma	3.71e-05	0.000307	CcSEcCtD
Methotrexate—Headache—Leflunomide—systemic scleroderma	3.69e-05	0.000305	CcSEcCtD
Methotrexate—Malnutrition—Prednisone—systemic scleroderma	3.69e-05	0.000305	CcSEcCtD
Methotrexate—Erythema—Prednisone—systemic scleroderma	3.69e-05	0.000305	CcSEcCtD
Methotrexate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	3.66e-05	0.000303	CcSEcCtD
Methotrexate—Asthenia—Lisinopril—systemic scleroderma	3.63e-05	0.000301	CcSEcCtD
Methotrexate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.63e-05	0.0003	CcSEcCtD
Methotrexate—Pruritus—Lisinopril—systemic scleroderma	3.58e-05	0.000296	CcSEcCtD
Methotrexate—Vomiting—Mycophenolic acid—systemic scleroderma	3.58e-05	0.000296	CcSEcCtD
Methotrexate—FPGS—Disease—CD247—systemic scleroderma	3.55e-05	0.00356	CbGpPWpGaD
Methotrexate—Rash—Mycophenolic acid—systemic scleroderma	3.55e-05	0.000293	CcSEcCtD
Methotrexate—Dermatitis—Mycophenolic acid—systemic scleroderma	3.54e-05	0.000293	CcSEcCtD
Methotrexate—Urticaria—Mycophenolate mofetil—systemic scleroderma	3.53e-05	0.000292	CcSEcCtD
Methotrexate—Headache—Mycophenolic acid—systemic scleroderma	3.52e-05	0.000291	CcSEcCtD
Methotrexate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	3.51e-05	0.00029	CcSEcCtD
Methotrexate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	3.51e-05	0.00029	CcSEcCtD
Methotrexate—Nausea—Leflunomide—systemic scleroderma	3.5e-05	0.00029	CcSEcCtD
Methotrexate—PGD—Disease—TGFBI—systemic scleroderma	3.49e-05	0.0035	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—SELP—systemic scleroderma	3.49e-05	0.0035	CbGpPWpGaD
Methotrexate—Vision blurred—Prednisone—systemic scleroderma	3.47e-05	0.000287	CcSEcCtD
Methotrexate—Diarrhoea—Lisinopril—systemic scleroderma	3.47e-05	0.000287	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—IL13—systemic scleroderma	3.43e-05	0.00344	CbGpPWpGaD
Methotrexate—Ill-defined disorder—Prednisone—systemic scleroderma	3.42e-05	0.000283	CcSEcCtD
Methotrexate—Anaemia—Prednisone—systemic scleroderma	3.41e-05	0.000282	CcSEcCtD
Methotrexate—PGD—NRF2 pathway—TGFB1—systemic scleroderma	3.39e-05	0.0034	CbGpPWpGaD
Methotrexate—Dizziness—Lisinopril—systemic scleroderma	3.35e-05	0.000277	CcSEcCtD
Methotrexate—Nausea—Mycophenolic acid—systemic scleroderma	3.34e-05	0.000276	CcSEcCtD
Methotrexate—TYMS—Cell Cycle—CENPA—systemic scleroderma	3.33e-05	0.00334	CbGpPWpGaD
Methotrexate—Malaise—Prednisone—systemic scleroderma	3.32e-05	0.000275	CcSEcCtD
Methotrexate—Vertigo—Prednisone—systemic scleroderma	3.31e-05	0.000274	CcSEcCtD
Methotrexate—FPGS—Metabolism—HSPG2—systemic scleroderma	3.27e-05	0.00328	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—HSPG2—systemic scleroderma	3.27e-05	0.00328	CbGpPWpGaD
Methotrexate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.27e-05	0.00027	CcSEcCtD
Methotrexate—SLC16A1—Hemostasis—RHOB—systemic scleroderma	3.26e-05	0.00327	CbGpPWpGaD
Methotrexate—Vomiting—Lisinopril—systemic scleroderma	3.22e-05	0.000266	CcSEcCtD
Methotrexate—Rash—Lisinopril—systemic scleroderma	3.19e-05	0.000264	CcSEcCtD
Methotrexate—Convulsion—Prednisone—systemic scleroderma	3.19e-05	0.000264	CcSEcCtD
Methotrexate—Dermatitis—Lisinopril—systemic scleroderma	3.19e-05	0.000264	CcSEcCtD
Methotrexate—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.18e-05	0.000263	CcSEcCtD
Methotrexate—Headache—Lisinopril—systemic scleroderma	3.17e-05	0.000262	CcSEcCtD
Methotrexate—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.14e-05	0.00026	CcSEcCtD
Methotrexate—Myalgia—Prednisone—systemic scleroderma	3.14e-05	0.00026	CcSEcCtD
Methotrexate—Arthralgia—Prednisone—systemic scleroderma	3.14e-05	0.00026	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.12e-05	0.000258	CcSEcCtD
Methotrexate—Discomfort—Prednisone—systemic scleroderma	3.1e-05	0.000256	CcSEcCtD
Methotrexate—SLC46A1—Disease—HSPG2—systemic scleroderma	3.05e-05	0.00305	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	3.05e-05	0.00305	CbGpPWpGaD
Methotrexate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.04e-05	0.000251	CcSEcCtD
Methotrexate—Nausea—Lisinopril—systemic scleroderma	3.01e-05	0.000249	CcSEcCtD
Methotrexate—Anaphylactic shock—Prednisone—systemic scleroderma	3.01e-05	0.000249	CcSEcCtD
Methotrexate—Infection—Prednisone—systemic scleroderma	2.99e-05	0.000247	CcSEcCtD
Methotrexate—SLC16A1—Hemostasis—CSK—systemic scleroderma	2.97e-05	0.00297	CbGpPWpGaD
Methotrexate—Nervous system disorder—Prednisone—systemic scleroderma	2.95e-05	0.000244	CcSEcCtD
Methotrexate—SLC46A1—Disease—CSK—systemic scleroderma	2.94e-05	0.00295	CbGpPWpGaD
Methotrexate—Dizziness—Mycophenolate mofetil—systemic scleroderma	2.93e-05	0.000243	CcSEcCtD
Methotrexate—Skin disorder—Prednisone—systemic scleroderma	2.92e-05	0.000242	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—CTGF—systemic scleroderma	2.92e-05	0.00293	CbGpPWpGaD
Methotrexate—Hyperhidrosis—Prednisone—systemic scleroderma	2.91e-05	0.000241	CcSEcCtD
Methotrexate—Anorexia—Prednisone—systemic scleroderma	2.87e-05	0.000237	CcSEcCtD
Methotrexate—Vomiting—Mycophenolate mofetil—systemic scleroderma	2.82e-05	0.000233	CcSEcCtD
Methotrexate—Rash—Mycophenolate mofetil—systemic scleroderma	2.8e-05	0.000231	CcSEcCtD
Methotrexate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	2.8e-05	0.000231	CcSEcCtD
Methotrexate—SLC16A1—Hemostasis—ITGAM—systemic scleroderma	2.79e-05	0.0028	CbGpPWpGaD
Methotrexate—PGD—Disease—HSPG2—systemic scleroderma	2.79e-05	0.00279	CbGpPWpGaD
Methotrexate—Headache—Mycophenolate mofetil—systemic scleroderma	2.78e-05	0.00023	CcSEcCtD
Methotrexate—SLC46A1—Disease—CD247—systemic scleroderma	2.77e-05	0.00277	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	2.76e-05	0.00277	CbGpPWpGaD
Methotrexate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.74e-05	0.000227	CcSEcCtD
Methotrexate—Insomnia—Prednisone—systemic scleroderma	2.72e-05	0.000225	CcSEcCtD
Methotrexate—Paraesthesia—Prednisone—systemic scleroderma	2.7e-05	0.000223	CcSEcCtD
Methotrexate—PGD—Disease—CSK—systemic scleroderma	2.69e-05	0.0027	CbGpPWpGaD
Methotrexate—Dyspepsia—Prednisone—systemic scleroderma	2.65e-05	0.000219	CcSEcCtD
Methotrexate—Nausea—Mycophenolate mofetil—systemic scleroderma	2.64e-05	0.000218	CcSEcCtD
Methotrexate—Decreased appetite—Prednisone—systemic scleroderma	2.61e-05	0.000216	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—SELP—systemic scleroderma	2.6e-05	0.00261	CbGpPWpGaD
Methotrexate—Fatigue—Prednisone—systemic scleroderma	2.59e-05	0.000215	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—HSPG2—systemic scleroderma	2.55e-05	0.00256	CbGpPWpGaD
Methotrexate—PGD—Disease—CD247—systemic scleroderma	2.53e-05	0.00254	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SMAD7—systemic scleroderma	2.52e-05	0.00253	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	2.51e-05	0.00251	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—CTGF—systemic scleroderma	2.48e-05	0.00249	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—CTGF—systemic scleroderma	2.48e-05	0.00249	CbGpPWpGaD
Methotrexate—Feeling abnormal—Prednisone—systemic scleroderma	2.48e-05	0.000205	CcSEcCtD
Methotrexate—AOX1—Disease—SMAD7—systemic scleroderma	2.46e-05	0.00247	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Prednisone—systemic scleroderma	2.46e-05	0.000203	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.46e-05	0.00246	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—RHOB—systemic scleroderma	2.43e-05	0.00243	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	2.41e-05	0.00241	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—CCL2—systemic scleroderma	2.4e-05	0.0024	CbGpPWpGaD
Methotrexate—Urticaria—Prednisone—systemic scleroderma	2.39e-05	0.000198	CcSEcCtD
Methotrexate—Body temperature increased—Prednisone—systemic scleroderma	2.38e-05	0.000197	CcSEcCtD
Methotrexate—Abdominal pain—Prednisone—systemic scleroderma	2.38e-05	0.000197	CcSEcCtD
Methotrexate—PGD—Metabolism—HSPG2—systemic scleroderma	2.33e-05	0.00234	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFBI—systemic scleroderma	2.3e-05	0.00231	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	2.28e-05	0.00229	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	2.27e-05	0.00228	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFBI—systemic scleroderma	2.25e-05	0.00226	CbGpPWpGaD
Methotrexate—DHFR—Disease—SMAD7—systemic scleroderma	2.24e-05	0.00224	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.22e-05	0.00222	CbGpPWpGaD
Methotrexate—Hypersensitivity—Prednisone—systemic scleroderma	2.22e-05	0.000183	CcSEcCtD
Methotrexate—ABCC4—Hemostasis—CSK—systemic scleroderma	2.21e-05	0.00222	CbGpPWpGaD
Methotrexate—ABCC4—Platelet degranulation—TGFB1—systemic scleroderma	2.19e-05	0.00219	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	2.16e-05	0.00216	CbGpPWpGaD
Methotrexate—Asthenia—Prednisone—systemic scleroderma	2.16e-05	0.000179	CcSEcCtD
Methotrexate—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	2.15e-05	0.00215	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	2.13e-05	0.00214	CbGpPWpGaD
Methotrexate—Pruritus—Prednisone—systemic scleroderma	2.13e-05	0.000176	CcSEcCtD
Methotrexate—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	2.08e-05	0.00209	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—ITGAM—systemic scleroderma	2.08e-05	0.00209	CbGpPWpGaD
Methotrexate—Diarrhoea—Prednisone—systemic scleroderma	2.06e-05	0.00017	CcSEcCtD
Methotrexate—DHFR—Disease—TGFBI—systemic scleroderma	2.05e-05	0.00205	CbGpPWpGaD
Methotrexate—Dizziness—Prednisone—systemic scleroderma	1.99e-05	0.000165	CcSEcCtD
Methotrexate—ALB—Folate Metabolism—CCL2—systemic scleroderma	1.96e-05	0.00196	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	1.94e-05	0.00195	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—CTGF—systemic scleroderma	1.93e-05	0.00194	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.93e-05	0.00194	CbGpPWpGaD
Methotrexate—Vomiting—Prednisone—systemic scleroderma	1.91e-05	0.000158	CcSEcCtD
Methotrexate—Rash—Prednisone—systemic scleroderma	1.9e-05	0.000157	CcSEcCtD
Methotrexate—Dermatitis—Prednisone—systemic scleroderma	1.89e-05	0.000157	CcSEcCtD
Methotrexate—Headache—Prednisone—systemic scleroderma	1.88e-05	0.000156	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.86e-05	0.00187	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HSPG2—systemic scleroderma	1.84e-05	0.00184	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	1.82e-05	0.00183	CbGpPWpGaD
Methotrexate—AOX1—Disease—HSPG2—systemic scleroderma	1.8e-05	0.0018	CbGpPWpGaD
Methotrexate—Nausea—Prednisone—systemic scleroderma	1.79e-05	0.000148	CcSEcCtD
Methotrexate—MTHFR—Disease—CSK—systemic scleroderma	1.78e-05	0.00178	CbGpPWpGaD
Methotrexate—PGD—Metabolism—CTGF—systemic scleroderma	1.77e-05	0.00177	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.74e-05	0.00174	CbGpPWpGaD
Methotrexate—AOX1—Disease—CSK—systemic scleroderma	1.73e-05	0.00174	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.68e-05	0.00168	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CD247—systemic scleroderma	1.67e-05	0.00167	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	1.65e-05	0.00166	CbGpPWpGaD
Methotrexate—DHFR—Disease—HSPG2—systemic scleroderma	1.63e-05	0.00164	CbGpPWpGaD
Methotrexate—AOX1—Disease—CD247—systemic scleroderma	1.63e-05	0.00163	CbGpPWpGaD
Methotrexate—DHFR—Disease—CSK—systemic scleroderma	1.58e-05	0.00158	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	1.55e-05	0.00156	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—HSPG2—systemic scleroderma	1.54e-05	0.00154	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—NOS3—systemic scleroderma	1.52e-05	0.00152	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—HSPG2—systemic scleroderma	1.5e-05	0.00151	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL1B—systemic scleroderma	1.48e-05	0.00149	CbGpPWpGaD
Methotrexate—DHFR—Disease—CD247—systemic scleroderma	1.48e-05	0.00149	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.46e-05	0.00147	CbGpPWpGaD
Methotrexate—ABCC3—NRF2 pathway—TGFB1—systemic scleroderma	1.44e-05	0.00144	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.4e-05	0.0014	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—MMP1—systemic scleroderma	1.4e-05	0.0014	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—HSPG2—systemic scleroderma	1.37e-05	0.00137	CbGpPWpGaD
Methotrexate—ABCC4—NRF2 pathway—TGFB1—systemic scleroderma	1.35e-05	0.00135	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.32e-05	0.00132	CbGpPWpGaD
Methotrexate—FPGS—Disease—NOS3—systemic scleroderma	1.29e-05	0.00129	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—NOS3—systemic scleroderma	1.27e-05	0.00127	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SMAD7—systemic scleroderma	1.27e-05	0.00127	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.25e-05	0.00125	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—HSPG2—systemic scleroderma	1.25e-05	0.00125	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—HSPG2—systemic scleroderma	1.19e-05	0.0012	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	1.18e-05	0.00118	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SELP—systemic scleroderma	1.18e-05	0.00118	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CTGF—systemic scleroderma	1.17e-05	0.00117	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFBI—systemic scleroderma	1.16e-05	0.00116	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CTGF—systemic scleroderma	1.14e-05	0.00114	CbGpPWpGaD
Methotrexate—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	1.14e-05	0.00114	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	1.13e-05	0.00113	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RHOB—systemic scleroderma	1.1e-05	0.0011	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—HSPG2—systemic scleroderma	1.09e-05	0.0011	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—NOS3—systemic scleroderma	1.08e-05	0.00108	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—NOS3—systemic scleroderma	1.08e-05	0.00108	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MMP1—systemic scleroderma	1.04e-05	0.00104	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CTGF—systemic scleroderma	1.04e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NOS3—systemic scleroderma	1.01e-05	0.00102	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NOS3—systemic scleroderma	1e-05	0.00101	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—TGFB1—systemic scleroderma	1e-05	0.00101	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CSK—systemic scleroderma	1e-05	0.001	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—TGFB1—systemic scleroderma	9.89e-06	0.000991	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—HSPG2—systemic scleroderma	9.88e-06	0.00099	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	9.69e-06	0.000972	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CTGF—systemic scleroderma	9.44e-06	0.000946	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	9.44e-06	0.000946	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	9.42e-06	0.000944	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—ITGAM—systemic scleroderma	9.41e-06	0.000943	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HSPG2—systemic scleroderma	9.24e-06	0.000926	CbGpPWpGaD
Methotrexate—PGD—Disease—NOS3—systemic scleroderma	9.19e-06	0.000921	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CTGF—systemic scleroderma	9.04e-06	0.000907	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CSK—systemic scleroderma	8.93e-06	0.000895	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	8.75e-06	0.000877	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—HSPG2—systemic scleroderma	8.6e-06	0.000862	CbGpPWpGaD
Methotrexate—FPGS—Disease—TGFB1—systemic scleroderma	8.53e-06	0.000855	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—NOS3—systemic scleroderma	8.41e-06	0.000843	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD247—systemic scleroderma	8.39e-06	0.000841	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CTGF—systemic scleroderma	8.3e-06	0.000832	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—HSPG2—systemic scleroderma	7.74e-06	0.000776	CbGpPWpGaD
Methotrexate—PGD—Metabolism—NOS3—systemic scleroderma	7.7e-06	0.000771	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NOS3—systemic scleroderma	7.56e-06	0.000757	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CTGF—systemic scleroderma	7.49e-06	0.00075	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	7.36e-06	0.000737	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.15e-06	0.000717	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HSPG2—systemic scleroderma	6.81e-06	0.000683	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TGFB1—systemic scleroderma	6.7e-06	0.000672	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TGFB1—systemic scleroderma	6.64e-06	0.000666	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CTGF—systemic scleroderma	6.52e-06	0.000653	CbGpPWpGaD
Methotrexate—PGD—Disease—TGFB1—systemic scleroderma	6.08e-06	0.000609	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NOS3—systemic scleroderma	6.06e-06	0.000608	CbGpPWpGaD
Methotrexate—AOX1—Disease—NOS3—systemic scleroderma	5.92e-06	0.000594	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CTGF—systemic scleroderma	5.87e-06	0.000588	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CTGF—systemic scleroderma	5.57e-06	0.000559	CbGpPWpGaD
Methotrexate—DHFR—Disease—NOS3—systemic scleroderma	5.39e-06	0.00054	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CTGF—systemic scleroderma	5.16e-06	0.000517	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—NOS3—systemic scleroderma	5.08e-06	0.000509	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TGFB1—systemic scleroderma	5e-06	0.000501	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—NOS3—systemic scleroderma	4.96e-06	0.000497	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MMP1—systemic scleroderma	4.72e-06	0.000473	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—NOS3—systemic scleroderma	4.51e-06	0.000452	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.39e-06	0.00044	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.32e-06	0.000433	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HSPG2—systemic scleroderma	4.2e-06	0.000421	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—NOS3—systemic scleroderma	4.11e-06	0.000412	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—systemic scleroderma	4.01e-06	0.000402	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—NOS3—systemic scleroderma	3.94e-06	0.000395	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—systemic scleroderma	3.92e-06	0.000392	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HSPG2—systemic scleroderma	3.68e-06	0.000369	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—NOS3—systemic scleroderma	3.61e-06	0.000362	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—systemic scleroderma	3.56e-06	0.000357	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NOS3—systemic scleroderma	3.42e-06	0.000343	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—NOS3—systemic scleroderma	3.26e-06	0.000327	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CTGF—systemic scleroderma	3.19e-06	0.000319	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOS3—systemic scleroderma	3.05e-06	0.000306	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NOS3—systemic scleroderma	2.84e-06	0.000284	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CTGF—systemic scleroderma	2.79e-06	0.00028	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NOS3—systemic scleroderma	2.55e-06	0.000256	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NOS3—systemic scleroderma	2.43e-06	0.000243	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—systemic scleroderma	2.26e-06	0.000227	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NOS3—systemic scleroderma	2.25e-06	0.000225	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—systemic scleroderma	2.02e-06	0.000202	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NOS3—systemic scleroderma	1.39e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NOS3—systemic scleroderma	1.21e-06	0.000122	CbGpPWpGaD
